1. Depression and the cardiovascular system: increasing evidence of a link and therapeutic implications
- Author
-
Giuseppe Marano, Giuseppe Biondi-Zoccai, Marzia Lotrionte, Enrico Romagnoli, Marianna Mazza, Desiree Harnic, and Antonio Abbate
- Subjects
medicine.medical_specialty ,Disease ,Antidepressive Agents, Tricyclic ,law.invention ,Randomized controlled trial ,law ,Epidemiology ,Internal Medicine ,Humans ,Medicine ,Psychiatry ,Depression (differential diagnoses) ,chemistry.chemical_classification ,Clinical Trials as Topic ,Depressive Disorder ,antidepressant drug ,cardiovascular disease ,comorbidity ,depression ,randomized clinical trial ,business.industry ,General Medicine ,Serotonin reuptake ,medicine.disease ,Comorbidity ,Antidepressive Agents ,chemistry ,Cardiovascular Diseases ,Cardiology and Cardiovascular Medicine ,business ,Selective Serotonin Reuptake Inhibitors ,Tricyclic - Abstract
This review explores the epidemiological evidence for the relationship between depression and cardiovascular disease from a mechanistic standpoint. It is important to examine the biological, behavioral and social mechanisms to improve outcomes for depressed cardiac patients. A number of plausible biobehavioral mechanisms linking depression and cardiovascular disease have been identified. Tricyclic antidepressants have various effects on the cardiovascular system, while selective serotonin reuptake inhibitors are not associated with adverse cardiac effects and should, therefore, be the preferred choice for the treatment of most patients with comorbid depression and cardiovascular disease.
- Published
- 2009
- Full Text
- View/download PDF